CA2940536A1 - 6-substituted estradiol derivatives for the treatment of alzheimer's disease - Google Patents

6-substituted estradiol derivatives for the treatment of alzheimer's disease Download PDF

Info

Publication number
CA2940536A1
CA2940536A1 CA2940536A CA2940536A CA2940536A1 CA 2940536 A1 CA2940536 A1 CA 2940536A1 CA 2940536 A CA2940536 A CA 2940536A CA 2940536 A CA2940536 A CA 2940536A CA 2940536 A1 CA2940536 A1 CA 2940536A1
Authority
CA
Canada
Prior art keywords
methyl
cyclopenta
decahydro
phenanthrene
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2940536A
Other languages
English (en)
French (fr)
Inventor
James G. Yarger
Steven H. Nye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endece LLC
Original Assignee
Endece LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endece LLC filed Critical Endece LLC
Publication of CA2940536A1 publication Critical patent/CA2940536A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2940536A 2014-03-19 2015-03-19 6-substituted estradiol derivatives for the treatment of alzheimer's disease Abandoned CA2940536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955578P 2014-03-19 2014-03-19
US61/955,578 2014-03-19
PCT/US2015/021538 WO2015143201A2 (en) 2014-03-19 2015-03-19 6-substituted estradiol derivatives for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CA2940536A1 true CA2940536A1 (en) 2015-09-24

Family

ID=54141046

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2940536A Abandoned CA2940536A1 (en) 2014-03-19 2015-03-19 6-substituted estradiol derivatives for the treatment of alzheimer's disease

Country Status (11)

Country Link
US (1) US20150265630A1 (https=)
EP (1) EP3119402A4 (https=)
JP (1) JP2017512769A (https=)
KR (1) KR20160136363A (https=)
CN (1) CN106255501A (https=)
AU (2) AU2015231172A1 (https=)
BR (1) BR112016021408A2 (https=)
CA (1) CA2940536A1 (https=)
MX (1) MX2016012045A (https=)
SG (1) SG11201607693WA (https=)
WO (1) WO2015143201A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020247407A1 (en) * 2019-06-03 2020-12-10 Aihol Corporation Hyaluronan conjugates and uses thereof
US20210024568A1 (en) * 2019-07-23 2021-01-28 Endece Llc Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
CN106420767A (zh) * 2011-03-21 2017-02-22 安德斯有限责任公司 用于神经轴突的髓鞘再生的6‑取代的雌二醇衍生物

Also Published As

Publication number Publication date
CN106255501A (zh) 2016-12-21
JP2017512769A (ja) 2017-05-25
EP3119402A2 (en) 2017-01-25
SG11201607693WA (en) 2016-10-28
BR112016021408A2 (pt) 2017-12-19
KR20160136363A (ko) 2016-11-29
EP3119402A4 (en) 2017-11-01
AU2015231172A1 (en) 2016-09-08
MX2016012045A (es) 2017-01-19
WO2015143201A2 (en) 2015-09-24
AU2018201003A1 (en) 2018-03-01
US20150265630A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
JP5981434B2 (ja) 選択的ＥＲ−βアゴニストとしての６−置換デメチル−エストラジオール誘導体
CA2781627C (en) 6-substituted estradiol derivatives and methods of use
WO2019238046A1 (zh) 喜树碱衍生物及其制备方法和应用
JP2025509698A (ja) Ｓｉｒｎａバイオアベイラビリティを改善するためのｇａｌｎａｃ組成物
JP6174563B2 (ja) 神経軸索の再ミエリン化における使用のための６−置換エストラジオール誘導体
CA2940536A1 (en) 6-substituted estradiol derivatives for the treatment of alzheimer's disease
CN115475253B (zh) 拉帕替尼-癌细胞干性抑制剂偶联物、制法、药物组合物和应用
WO2013052465A1 (en) [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
US20160194274A1 (en) Phenanthrene derivatives for use as medicaments
US20230097440A1 (en) Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states
KR101634758B1 (ko) 에스트로겐 수용체 리간드로서의 2-하이드록시-7-메틸 옥타하이드로페난트렌 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 약학 조성물
CA3153282A1 (en) Treatment or prevention of leukaemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160822

FZDE Dead

Effective date: 20200106